[11] [56] In December 2024, the FDA approved tirzepatide (Zepbound) as the first medication to be used in the treatment of moderate to severe obstructive sleep apnea
This muscle-sparing effect is valuable for body recomposition goals and maintaining metabolic rate during fat loss phases
These medications include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)
These evaluations allow for timely adjustments to dosing, supportive therapies, and recovery strategies while tracking progress throughout the treatment program
LYMPHATIC & DRAINAGE AID: Features Galium aparine (Cleavers) to support the lymphatic system and promote healthy fluid balance, ensuring your bodys primary elimination pathways remain active and efficient
This route of administration allows for gradual absorption and sustained therapeutic effect